FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Thromb Haemost / von Willebrand factor A1 domain can adequately substitute fo...
Journal of thrombosis and haemostasis : JTH2006; 4(10); 2151-2161; doi: 10.1111/j.1538-7836.2006.02111.x

von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen.

Abstract: Binding of von Willebrand factor (VWF) to platelet GPIbalpha and to collagen is attributed to VWF A1 and A3 domains, respectively. Objective: Using VWF, VWF lacking A1 (DeltaA1-VWF) or A3 (DeltaA3-VWF) and VWF with defective A3 (H1786A-VWF), in combination with recombinant A1 (residues 1262-1492) or A3 (residues 1671-1878), fused to glutathione-S-transferase (GST-A1 and GST-A3), we have re-investigated the role of A1 in platelet recruitment to surfaces of collagen. Results: In flow, measurable binding of DeltaA3-VWF occurred to horse tendon, but also to human type III collagen. GST-A1 and GST-A3 both competed for binding of DeltaA1-VWF and DeltaA3-VWF to horse tendon collagen fibrils in static conditions and to human collagen III during plasmon surface resonance studies, substantiating overlapping binding sites on both collagens for A1 and A3. Heparin did not affect A3-mediated binding of VWF and DeltaA1-VWF, but inhibited binding to horse tendon collagen of GST-A1 and DeltaA3-VWF. Furthermore, A1-mediated binding to type III collagen of DeltaA3-VWF binding was strongly salt-sensitive. During perfusions at wall shear rate 2500 s(-1) of calcein-labeled platelets in reconstituted blood, DeltaA3-VWF and H1786A-VWF triggered platelet binding to horse tendon collagen comparably and as potently as VWF, and to human type III collagen, only fivefold less potently, DeltaA1-VWF being inactive. Additional flow-controlled interaction studies with DeltaA3-VWF, H1786A-VWF, the collagen-VWF antagonist saratin, heparin and the VWF neutralizing antibody 82D6A3 confirmed that H1786A-VWF binds to collagen exclusively via A1. Conclusions: Hence, in shear forces the VWF A1 domain can assume the role of A3 to trigger substantial platelet recruitment to human collagen fibres.
Get Full Text
Publication Date: 2006-06-29 PubMed ID: 16805860DOI: 10.1111/j.1538-7836.2006.02111.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study investigates how the von Willebrand factor (VWF) protein’s A1 domain can effectively replace the A3 domain in attracting circulating platelets to collagen, which is instrumental in blood clotting.

Research Methods

  • The scientists utilized various versions of VWF for the study: the normal form, a form lacking the A1 domain (DeltaA1-VWF), a form lacking the A3 domain (DeltaA3-VWF), and a form with a defective A3 domain (H1786A-VWF).
  • These were combined with custom-made A1 and A3 domains fused to the protein glutathione-S-transferase (GST-A1 and GST-A3).
  • The role of the A1 domain in attracting platelets to collagen surfaces was reexamined through these combinations.

Findings

  • In a flowing environment, DeltaA3-VWF showed observable binding to horse tendon collagen and human type III collagen.
  • In static conditions, both GST-A1 and GST-A3 competed for binding with DeltaA1-VWF and DeltaA3-VWF to collagen fibrils from horse tendons.
  • This competition also took place on human collagen III during surface plasmon resonance studies, suggesting the A1 and A3 domains have overlapping binding sites on both types of collagen.
  • The presence of a blood thinner, heparin, did not affect A3-mediated binding of VWF and DeltaA1-VWF but did inhibit GST-A1 and DeltaA3-VWF’s binding to horse tendon collagen.
  • A1-mediated binding of DeltaA3-VWF to type III collagen was greatly influenced by salt.

Conclusions

  • During perfusions, DeltaA3-VWF and H1786A-VWF triggered platelets to bind to collagen just as effectively as the normal VWF would.
  • However, a form lacking the A1 domain (DeltaA1-VWF) was inactive in the same conditions.
  • In cases of high shear forces, the A1 domain of the VWF protein can replace the A3 domain to trigger significant platelet binding to collagen fibres, pivotal in blood clotting.

This study provides significant insights into the role of different domains of VWF in triggering platelet binding to collagen fibres during blood clotting.

Cite This Article

APA
Bonnefoy A, Romijn RA, Vandervoort PA, VAN Rompaey I, Vermylen J, Hoylaerts MF. (2006). von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen. J Thromb Haemost, 4(10), 2151-2161. https://doi.org/10.1111/j.1538-7836.2006.02111.x

Publication

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7933
NlmUniqueID: 101170508
Country: England
Language: English
Volume: 4
Issue: 10
Pages: 2151-2161

Researcher Affiliations

Bonnefoy, A
  • Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium.
Romijn, R A
    Vandervoort, P A H
      VAN Rompaey, I
        Vermylen, J
          Hoylaerts, M F

            MeSH Terms

            • Animals
            • Binding Sites
            • Blood Platelets / metabolism
            • Collagen / chemistry
            • Dose-Response Relationship, Drug
            • Glutathione Transferase / metabolism
            • Horses
            • Humans
            • Platelet Adhesiveness
            • Protein Binding
            • Protein Structure, Tertiary
            • Recombinant Proteins / chemistry
            • Salivary Proteins and Peptides / chemistry
            • Stress, Mechanical
            • Surface Plasmon Resonance
            • Time Factors
            • von Willebrand Factor / chemistry
            • von Willebrand Factor / genetics
            • von Willebrand Factor / physiology

            Citations

            This article has been cited 26 times.
            1. Pierre-Louis O, Resiere D, Alphonsine C, Dantin F, Banydeen R, Dubois MD, Mehdaoui H, Neviere R. Increased Binding of von Willebrand Factor to Sub-Endothelial Collagen May Facilitate Thrombotic Events Complicating Bothrops lanceolatus Envenomation in Humans. Toxins (Basel) 2023 Jul 3;15(7).
              doi: 10.3390/toxins15070441pubmed: 37505710google scholar: lookup
            2. Maas DPMSM, Atiq F, Blijlevens NMA, Brons PPT, Krouwel S, Laros-van Gorkom BAP, Leebeek FWG, Nieuwenhuizen L, Schoormans SCM, Simons A, Meijer D, van Heerde WL, Schols SEM. Von Willebrand disease type 2M: Correlation between genotype and phenotype. J Thromb Haemost 2022 Feb;20(2):316-327.
              doi: 10.1111/jth.15586pubmed: 34758185google scholar: lookup
            3. Wang Q, Liu W, Fan J, Guo J, Shen F, Ma Z, Ruan C, Guo L, Jiang M, Zhao Y. von Willebrand factor promotes platelet-induced metastasis of osteosarcoma through activation of the VWF-GPIb axis. J Bone Oncol 2020 Dec;25:100325.
              doi: 10.1016/j.jbo.2020.100325pubmed: 33101888google scholar: lookup
            4. Flood VH, Slobodianuk TL, Keesler D, Lohmeier HK, Fahs S, Zhang L, Simpson P, Montgomery RR. von Willebrand factor binding to myosin assists in coagulation. Blood Adv 2020 Jan 14;4(1):174-180.
              doi: 10.1182/bloodadvances.2019000533pubmed: 31935285google scholar: lookup
            5. Howes JM, Knäuper V, Malcor JD, Farndale RW. Cleavage by MMP-13 renders VWF unable to bind to collagen but increases its platelet reactivity. J Thromb Haemost 2020 Apr;18(4):942-954.
              doi: 10.1111/jth.14729pubmed: 31894636google scholar: lookup
            6. Machha VR, Tischer A, Moon-Tasson L, Auton M. The Von Willebrand Factor A1-Collagen III Interaction Is Independent of Conformation and Type 2 Von Willebrand Disease Phenotype. J Mol Biol 2017 Jan 6;429(1):32-47.
              doi: 10.1016/j.jmb.2016.11.014pubmed: 27889474google scholar: lookup
            7. Tischer A, Campbell JC, Machha VR, Moon-Tasson L, Benson LM, Sankaran B, Kim C, Auton M. Mutational Constraints on Local Unfolding Inhibit the Rheological Adaptation of von Willebrand Factor. J Biol Chem 2016 Feb 19;291(8):3848-59.
              doi: 10.1074/jbc.M115.703850pubmed: 26677223google scholar: lookup
            8. Flood VH, Schlauderaff AC, Haberichter SL, Slobodianuk TL, Jacobi PM, Bellissimo DB, Christopherson PA, Friedman KD, Gill JC, Hoffmann RG, Montgomery RR. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood 2015 Apr 2;125(14):2297-304.
              doi: 10.1182/blood-2014-11-610824pubmed: 25662333google scholar: lookup
            9. Madabhushi SR, Zhang C, Kelkar A, Dayananda KM, Neelamegham S. Platelet GpIba binding to von Willebrand Factor under fluid shear:contributions of the D′D3-domain, A1-domain flanking peptide and O-linked glycans. J Am Heart Assoc 2014 Oct 23;3(5):e001420.
              doi: 10.1161/JAHA.114.001420pubmed: 25341886google scholar: lookup
            10. Bryckaert M, Rosa JP, Denis CV, Lenting PJ. Of von Willebrand factor and platelets. Cell Mol Life Sci 2015 Jan;72(2):307-26.
              doi: 10.1007/s00018-014-1743-8pubmed: 25297919google scholar: lookup
            11. Tischer A, Madde P, Moon-Tasson L, Auton M. Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease. Biophys J 2014 Sep 2;107(5):1185-1195.
              doi: 10.1016/j.bpj.2014.07.026pubmed: 25185554google scholar: lookup
            12. Shida Y, Rydz N, Stegner D, Brown C, Mewburn J, Sponagle K, Danisment O, Crawford B, Vidal B, Hegadorn CA, Pruss CM, Nieswandt B, Lillicrap D. Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and α2β1-mediated collagen binding in thrombus formation. Blood 2014 Sep 11;124(11):1799-807.
              doi: 10.1182/blood-2013-09-521484pubmed: 25051961google scholar: lookup
            13. Springer TA. von Willebrand factor, Jedi knight of the bloodstream. Blood 2014 Aug 28;124(9):1412-25.
              doi: 10.1182/blood-2014-05-378638pubmed: 24928861google scholar: lookup
            14. Rauch A, Wohner N, Christophe OD, Denis CV, Susen S, Lenting PJ. On the versatility of von Willebrand factor. Mediterr J Hematol Infect Dis 2013;5(1):e2013046.
              doi: 10.4084/MJHID.2013.046pubmed: 23936617google scholar: lookup
            15. Neeves KB, Onasoga AA, Hansen RR, Lilly JJ, Venckunaite D, Sumner MB, Irish AT, Brodsky G, Manco-Johnson MJ, Di Paola JA. Sources of variability in platelet accumulation on type 1 fibrillar collagen in microfluidic flow assays. PLoS One 2013;8(1):e54680.
              doi: 10.1371/journal.pone.0054680pubmed: 23355889google scholar: lookup
            16. Min J, Lukowski ZL, Levine MA, Meyers CA, Beattie AR, Schultz GS, Samuelson DA, Sherwood MB. Prevention of ocular scarring post glaucoma filtration surgery using the inflammatory cell and platelet binding modulator saratin in a rabbit model. PLoS One 2012;7(4):e35627.
              doi: 10.1371/journal.pone.0035627pubmed: 22558182google scholar: lookup
            17. Auton M, Sowa KE, Behymer M, Cruz MA. N-terminal flanking region of A1 domain in von Willebrand factor stabilizes structure of A1A2A3 complex and modulates platelet activation under shear stress. J Biol Chem 2012 Apr 27;287(18):14579-85.
              doi: 10.1074/jbc.M112.348573pubmed: 22431729google scholar: lookup
            18. Hansen RR, Tipnis AA, White-Adams TC, Di Paola JA, Neeves KB. Characterization of collagen thin films for von Willebrand factor binding and platelet adhesion. Langmuir 2011 Nov 15;27(22):13648-58.
              doi: 10.1021/la2023727pubmed: 21967679google scholar: lookup
            19. Coburn LA, Damaraju VS, Dozic S, Eskin SG, Cruz MA, McIntire LV. GPIbα-vWF rolling under shear stress shows differences between type 2B and 2M von Willebrand disease. Biophys J 2011 Jan 19;100(2):304-12.
              doi: 10.1016/j.bpj.2010.11.084pubmed: 21244826google scholar: lookup
            20. Dayananda KM, Singh I, Mondal N, Neelamegham S. von Willebrand factor self-association on platelet GpIbalpha under hydrodynamic shear: effect on shear-induced platelet activation. Blood 2010 Nov 11;116(19):3990-8.
              doi: 10.1182/blood-2010-02-269266pubmed: 20696943google scholar: lookup
            21. Ying J, Ling Y, Westfield LA, Sadler JE, Shao JY. Unfolding the A2 domain of von Willebrand factor with the optical trap. Biophys J 2010 Apr 21;98(8):1685-93.
              doi: 10.1016/j.bpj.2009.12.4324pubmed: 20409490google scholar: lookup
            22. Flood VH, Lederman CA, Wren JS, Christopherson PA, Friedman KD, Hoffmann RG, Montgomery RR. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost 2010 Jun;8(6):1431-3.
              doi: 10.1111/j.1538-7836.2010.03869.xpubmed: 20345715google scholar: lookup
            23. Singh I, Themistou E, Porcar L, Neelamegham S. Fluid shear induces conformation change in human blood protein von Willebrand factor in solution. Biophys J 2009 Mar 18;96(6):2313-20.
              doi: 10.1016/j.bpj.2008.12.3900pubmed: 19289057google scholar: lookup
            24. Ruggeri ZM. Platelet adhesion under flow. Microcirculation 2009 Jan;16(1):58-83.
              doi: 10.1080/10739680802651477pubmed: 19191170google scholar: lookup
            25. Cheng C, Liu K, Zhang J, Han Y, Zhang T, Hou Y, Bai G. Ginsenoside CK targets PHD2 to prevent platelet adhesion and enhance blood circulation by modifying the three-dimensional arrangement of collagen. Acta Pharm Sin B 2025 Mar;15(3):1497-1513.
              doi: 10.1016/j.apsb.2024.12.038pubmed: 40370536google scholar: lookup
            26. Xu W, Tan X, Li ML, Xu H, Villegas J, Fu H. Von Willebrand factor and hematogenous cancer metastasis under flow. Front Cell Dev Biol 2024;12:1435718.
              doi: 10.3389/fcell.2024.1435718pubmed: 39282473google scholar: lookup
            Subscribe to our newsletter
            Join 99,075 horse owners like you who receive our email updates on horse health and nutrition.